From its beginnings as a small company in Aargau to its rise as a global CDMO leader, Siegfried embodies strategic growth, innovation and a strong commitment to pharmaceutical sustainability.
Founded in 1873, Siegfried has evolved from a modest team of 12 to an influential global CDMO, specializing in the development of APIs and finished dosage forms. Currently in Evionnaz for 66 years, Siegfried, headed by Marcel Signer, acquired the Evionnaz site in 2015, strengthening its position as a leading CDMO.
An attractive work-life balance in the canton of Valais
With 380 employees, the Evionnaz site is building a new R&D building to double its development capacity, creating 40 high-value jobs. Siegfried’s success is based on the expertise of its staff, offering small and large-scale production services as well as regulatory and quality support.The canton of Valais offers a balance between work and private life, with an inspiring natural environment. Siegfried works closely with local institutions, reinforcing its commitment to innovation and sustainable development.
A legacy of innovation and excellence
Today, sustainability is at the heart of Siegfried’s operations, responding to societal expectations and customer demands. With its heritage of innovation, Siegfried is positioned for a promising future in global healthcare, combining quality, innovation and sustainability.
